Margin collapse missed guidance; volume recovery hinges on Q3-Q4 and unproven capex
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 5/10
Grade C
Missed 26-27% EBITDA margin guidance; delivered 20.9%. FY27 cap-ex doubled from ₹200-250 Cr plan.
Cautiously Optimistic
next 1–2 quarters
Cautiously Optimistic
multi-year
Revenue momentum (+23.6%) masks a severe margin miss: Q2 EBITDA margin fell to 20.9% vs. prior 26-27% guidance. PAT collapsed 31.8% YoY despite top-line growth, driven by logistics/energy headwinds and ATBS destocking. Recovery hinges on unproven capex projects and uncertain H2 destocking rebound.
₹680.2 Cr
Revenue · +23.6% YoY₹78.4 Cr
Reported PAT · −31.8% YoYCompressing
Margins · vs guidance: OverstatedDid the claims hold up?
FY27 end EBITDA margin around 24%
MISSQ2 EBITDA margin 20.9%, down 530 bps YoY from 26.2%
Volume recovery in H2 FY27 on ATBS improvement
PartialATBS destocking in Q2 suppressed demand; recovery unproven
INR 500 Cr capex will have revenue contribution from Q3 onwards
PartialNew specialty products still under trial; April commercialization targeted
20%-25% FY27 top-line growth over FY26
METCurrent ₹680.2 Cr at 23.6% YoY; H1 ₹1,387 Cr at 25% YoY
Earnings quality
What changed since the last call
EBITDA margin guidance cut
DowngradePrior 26-27% → now ~24% for FY27 end, 25-26% for FY28. Q2 delivered only 20.9%.
Capex plan doubled
UpgradeFrom ₹200-250 Cr to ₹500 Cr announced + ₹500 Cr additional capex under discussion (pending land acquisition).
ATBS outlook downgraded
DowngradeQ2 destocking led to demand miss. Recovery now expected Q3-Q4 FY27 instead of being built in earlier.
Volume growth trajectory revised
NeutralPrior 15% FY27 growth guidance; now 20-25% top-line growth targeting, but mix-weighted (ATBS shift to Q3-Q4).
The Q&A
Analysts pressed hard on margin recovery path, ATBS demand, new capex ROI, and VOPL timeline. Management held firm on 25-26% FY28 margin but withheld second capex details (land deal still in progress). Q&A exposed execution uncertainty on new projects.
New capex chemistry focus — Rohit Nagraj, 360 ONE Capital
PartialProducts related to existing segments (fragrances, personal care, water treatment, oil fields); tested over last year; commercialization starting April.
ATBS destocking timeline — Nilesh Ghuge, HDFC Securities
PartialMeaningful improvement in Q3 looking strong; definitely recovery in H2. Third/fourth quarters better volume.
FY27 margin guidance — Nilesh Ghuge, HDFC Securities
AnsweredAround 24% EBITDA margin by FY27 end. For FY28, expecting 25-26%.
VOPL capex ROI & timeline — Naushad Chaudhary, Aditya Birla Mutual Funds
PartialRamp-up starts April; takes one year to optimize. Similar 15-20% ROI as prior projects. Land acquisition clarity in 6 months.
New product revenue potential — Surya Narayan Patra, PhillipCapital
AnsweredVOPL expected to cross INR 75-100 Cr revenue in FY28-FY29. MEHQ alone INR 100 Cr of INR 3000-4000 Cr value chain.
Margin recovery path — Surya Narayan Patra, PhillipCapital
PartialATBS shift to Q3-Q4 depressed Q2 mix. Worst is behind us. Logistics cooling in Q3; expect improvement.
Product mix H1 FY27 — Abhijit Akella, KIE
AnsweredATBS 27-28%; IBB 12-15%; Butyl Phenols 16-20%; AO 15-17%.
Guidance
FY27 +20-25% growth vs FY26
MediumImplies ₹816-850 Cr FY27 revenue. Q2 run-rate supports 23-24% growth if H2 recovers.
EBITDA ~24% by FY27 year-end
LowDown from prior 26-27% guidance. Q2 delivered 20.9%; requires 300 bps improvement in H2.
EBITDA 25-26% for FY28
MediumContingent on capex commercialization, ATBS recovery, and logistics cost normalization.
INR 500 Cr specialty chemicals capex FY27-FY28
HighMEHQ, BHA, fragrances, water treatment, oil fields. Funded via internal accruals.
Additional INR 500 Cr capex under discussion
LowLand acquisition in progress. Clarity expected within 6 months.
Risks the call surfaced
ATBS demand volatility
High27-28% of H1 revenue; Q2 destocking hit demand. Recovery unproven; could slip further if macro softens.
Margin compression risk
HighEBITDA margin fell 530 bps YoY to 20.9%; guidance of 26-27% missed. Logistics and energy costs could not be fully passed through.
New capex execution risk
MediumINR 500 Cr capex for specialty chemicals; VOPL April start with 1-year ramp. Revenue contribution ₹75-100 Cr by FY28-FY29 (not Q3 FY27). Execution history suggests delays.
Geopolitical headwind
MediumMiddle East conflict cited as drag on Q2 performance; impact on logistics, raw material sourcing, and customer demand.
Second capex uncertainty
MediumSecond ₹500 Cr capex announced in opening remarks but details withheld; land acquisition still in progress; clarity deferred 6 months.
Management
Score 6/10. Candid on challenges (Middle East, destocking, margin miss); detailed on product mix and capex ROI; hedged on second capex and new product timeline. Missed FY27 margin guidance (26-27% vs 20.9% delivered). Capex plan doubled. VOPL delays noted but project still proceeding.
1 · Q3-Q4 FY27
ATBS demand recovery on destocking end + logistics rate cooling
2 · April 2027
VOPL specialty chemical facility ramp-up begins (1-year optimization timeline)
3 · 6 months
Clarity on second ₹500 Cr capex project (land acquisition ongoing)
Recovery hinges on unproven capex projects and uncertain H2 destocking rebound.
Informational and educational content only. Not investment advice.